Polycystic Ovarian Syndrome (PCOS) Treatment Market

The forecast for the polycystic ovarian syndrome (PCOS) treatment market assists stakeholders in formulating their growth strategies. The market is expected to expand from US$ 3.98 billion in 2024 to US$ 5.26 billion by 2031, with an estimated CAGR of 5.4% from 2025 to 2031.The rising global prevalence of PCOS, along with a notable increase in healthcare expenditures on PCOS treatments, are key factors driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. For example, around 6 million women in the US are affected by PCOS, a prevalent hormonal disorder that elevates the risk of various health issues, including endometrial cancer, hypertension, type 2 diabetes, infertility, and stroke. Additionally, the Endocrine Society projects that the diagnosis and treatment of PCOS, the most common hormonal disorder among women of reproductive age, will incur a national cost of US$ 8 billion in 2020.

The development of innovative therapeutics is expected to introduce new trends in the polycystic ovarian syndrome (PCOS) treatment market during the forecast period.

Growth Drivers:Rising Global Incidence of PCOS Among Women Fuels Growth in the Polycystic Ovary Syndrome (PCOS) Treatment Market

Polycystic ovary syndrome (PCOS) is a widespread multifactorial endocrine disorder affecting women. The World Health Organization (WHO) estimates that PCOS impacts approximately 8-13% of women of reproductive age. It is the leading cause of anovulation and a significant contributor to infertility worldwide. Furthermore, about 70% of women with PCOS remain undiagnosed. Factors such as unhealthy diets and certain environmental influences can lead to the onset of PCOS. Obesity is a significant risk factor, as excess body weight can disrupt hormonal balance and insulin sensitivity, contributing to the condition's development. With the global obesity crisis escalating, more women are at risk of developing PCOS. According to the World Obesity Federation's 2022 World Obesity Atlas, over one billion people globally will be affected by obesity by 2030, including one in five women.

Moreover, the increasing incidence of PCOS has resulted in a heightened demand for effective treatment options. A variety of pharmaceutical and non-pharmaceutical treatments are available to help regulate hormone levels, enhance insulin sensitivity, and address other underlying issues related to PCOS. Therefore, the growing prevalence of PCOS among women worldwide is a significant driver of the polycystic ovarian syndrome (PCOS) treatment market's growth.

Restraint:Limited Availability of FDA-Approved Medications for PCOS Impedes the Polycystic Ovarian Syndrome (PCOS) Treatment Market

The availability of FDA-approved medications specifically designed to treat the complex symptoms and hormonal imbalances associated with polycystic ovary syndrome (PCOS) is limited. Despite the high prevalence of PCOS and its considerable impact on women's health, fertility, and quality of life, there are relatively few FDA-approved pharmaceutical options (often off-label) for treating this condition. This scarcity of FDA-approved medications poses challenges for healthcare providers and patients seeking effective, evidence-based treatments for PCOS. While off-label use of certain medications, such as oral contraceptives, insulin-sensitizing agents, and anti-androgens, is common in managing PCOS symptoms, the lack of dedicated therapies restricts comprehensive treatment options. Consequently, the limited availability of FDA-approved medications specifically for PCOS hinders the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Strategic Insights

Report Segmentation and Scope:The analysis of the polycystic ovarian syndrome (PCOS) treatment market has been conducted by examining the following segments: product and distribution channel.

By product, the polycystic ovarian syndrome (PCOS) treatment market is divided into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment accounted for the largest market share in 2023, while the clomiphene citrate segment is expected to exhibit the highest CAGR during the forecast period.

In terms of distribution channel, the polycystic ovarian syndrome (PCOS) treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the polycystic ovarian syndrome (PCOS) treatment market in 2023 and is projected to register the highest CAGR during the forecast period.

Regional Analysis:Geographically, the scope of the polycystic ovarian syndrome (PCOS) treatment market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held the largest market share. The increasing adoption of advanced medical device technologies, the rising prevalence of PCOS, and ongoing product innovations by key players are contributing to the growth of the polycystic ovarian syndrome (PCOS) treatment market in North America. According to the US Department of Health & Human Services, PCOS is a common cause of female infertility in the US, affecting approximately 6% to 12% (around 5 million) of women of reproductive age. A study published in July 2023 in the American Journal of Obstetrics and Gynecology reported an incidence rate of 42.5 cases of PCOS per 10,000 people annually in the US. Additionally, various organizations in the country are dedicated to comprehensive evaluation, raising awareness, and focusing on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively involved in research to understand the causes of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness support the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Report Scope

Industry Developments and Future Opportunities:Several strategic developments by leading players in the polycystic ovarian syndrome (PCOS) treatment market, as reported in company press releases, are highlighted below:

In April 2023, Celmatix launched a new PCOS drug program, introducing its latest therapeutic initiative targeting melatonin receptors outside the central nervous system (CNS). This therapeutic approach aims to fill a significant market gap for effective first-line therapies for various women's health issues, starting with PCOS and potentially extending to endometriosis and menopausal symptoms.

In January 2022, Celmatix Inc. announced a milestone achievement in its five-year, multi-target collaboration with Evotec. Evotec and Bayer AG reached a milestone to advance a PCOS drug program focused on a novel drug target identified by Celmatix into the hit identification phase.

Competitive Landscape and Key Companies:Prominent companies profiled in the polycystic ovarian syndrome (PCOS) treatment market report include Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc. These companies are dedicated to developing new technologies, enhancing existing products, and expanding their geographic reach to meet the increasing global consumer demand.